Understanding the economic burden of heart failure in China: impact on disease management and resource utilization

Journal of Medical Economics

Volumn 20, Issue 5, 2017, Pages 549-553

  Huang, Jun ^a   Yin, Hongjun ^b   Zhang, Milun ^c   Ni, Qian ^c   Xuan, Jianwei ^d  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b Centennial Scientific Co Ltd   (United States)

^c Novartis Pharmaceuticals (China) Oncology   (China)

^d SUN YAT SEN UNIVERSITY   (China)

Author keywords

burden; China; cost; healthcare utilization; Heart failure

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; CARDIOVASCULAR AGENT;

ADULT; AGED; ARTICLE; CARDIAC PATIENT; CHINA; CHINESE; COMPARATIVE STUDY; DEVELOPED COUNTRY; DISEASE ASSOCIATION; DRUG UTILIZATION; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HEART FAILURE; HOSPITAL PATIENT; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; ICD-10; MAJOR CLINICAL STUDY; MALE; PATIENT CARE; URBAN POPULATION; AGE; ECONOMICS; HOSPITAL CHARGE; INSURANCE; MIDDLE AGED; SEX DIFFERENCE; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; CARDIOVASCULAR AGENTS; CHINA; DRUG UTILIZATION; FEMALE; HEALTH EXPENDITURES; HEART FAILURE; HOSPITAL CHARGES; HOSPITALIZATION; HUMANS; INSURANCE CLAIM REVIEW; MALE; MIDDLE AGED; PATIENT READMISSION; SEX FACTORS;

EID: 85014924921     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.1080/13696998.2017.1297309     Document Type: Article

References (18)

1. Mendez GF, Cowie MR., The epidemiological features of heart failure in developing countries:a review of the literature. Int J Cardiol 2001;80:213-19
2. Gu DF, Huang GY, He J, et al. Investigation of prevalence and distributing feature of chronic heart failure in Chinese adult population. Chin J Cardiol 2003;31:3-6
3. Qian JF, Jiang H, Ge JB., The epidemiology and current therapy of chronic heart failure in China. Chin J Clin Med 2009;16:700-3
4. The US Centers for Disease Control and Prevention. CDC in China:factsheet. Centers for Disease Control and Prevention. Atlanta, USA. http://www.cdc.gov/globalhealth/countries/china/pdf/china.pdf. Accessed July 21, 2016
5. Fu R, Xiang J, Bao H, et al. Association between process indicators and in-hospital mortality among patients with chronic heart failure in China. Eur J Public Health 2015;25:373-8
6. Neumann T, Biermann J, Erbel R, et al. Heart failure:the commonest reason for hospital admission in Germany:medical and economic perspectives. Dtsch Arztebl Int 2009;106:269-75
7. Wang G, Zhang Z, Ayala C, et al. Costs of heart failure-related hospitalizations in patients aged 18 to 64years. Am J Manag Care 2010;16:769-76
8. Voigt J, Sasha John M, Taylor A, et al. A reevaluation of the costs of heart failure and its implications for allocation of health resources in the United States. Clin Cardiol 2014;37:312-21
9. Cook C, Cole G, Asaria P, et al. The annual global economic burden of heart failure. Int J Cardiol 2014;171:368-76
10. McMurray JJ, Adamopoulos S, Anker SD, et al.; ESC Committee for Practice Guidelines. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012:The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012;14:803-69
11. Reyes EB, Ha JW, Firdaus I, et al. Heart failure across Asia:Same healthcare burden but differences in organization of care. Int J Cardiol 2016;223:163-7
12. Yin X, Song F, Gong Y, et al. A systematic review of antibiotic utilization in China. J Antimicrob Chemother 2013;68:2445-52
13. Wu JR, Moser DK, De Jong MJ, et al. Defining an evidence-based cutpoint for medication adherence in heart failure. NIH Public Access 2009;157:285-91
14. Desai AS, Stevenson LW., Rehospitalization for heart failure:predict or prevent? Circulation 2012;126:501-6
15. Nicholson G, Gandra SR, Halbert RJ, et al. Patient-level costs of major cardiovascular conditions:a review of the international literature. Clinicoecon Outcomes Res 2016;8:495-506
16. Zhang Z, Chen J, Tang Z, et al. Direct medical costs of diabetes mellitus in China. Chin Health Resources 2007;10:162
17. Liang X, Gu D, Zhang H, et al. Drug therapy and direct medical cost among community patients with hypertension. Chinese Preventive Medicine Journal (Chinese). 2011;8:732-736
18. Yancy CW, Jessup M, Bozkurt B, et al. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure:An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure:A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol 2016;68:1476-88